Developed Markets May 31, 2021 / 12:13 pm UTC

DM Benefiting from Vaccines

By Mike Gallagher

Bottom line: Economic optimism could receive a new boost from the downtrend in DM COVID infections in May, which will likely continue in June with vaccination programs now reaching a large proportion of the population – though Japan and Australia continue to lag badly. 

Figure 1: Vaccine Benefits Coming Through      

Source: WHO, Datastream        

New confirmed COVID cases in the U.S. have now dipped to 19k on a seven day moving average basis, while large EZ countries are also seeing a clear downtrend in cases.  In the EZ this partially reflects the restrictions seen over the spring that are now starting to ease, but it also reflects the benefit of the accelerated pace of vaccinations.  EU countries have accelerated from 24% to 38% of the total population being vaccinated with at least 1 dose and most EU countries will likely now reach 70% of the adult population by July.  In the U.S. the May decline in new COVID cases is impressive, after the plateau in March and April and likely reflects the effects of widespread vaccination on reducing individual infections and also reducing transmissions (studies suggest by ½ to 2/3 for vaccinated people).  Finally, Canada has caught up with the U.S.

For economic forecasters this is good news and will likely translate into a further improvement in business and consumer confidence in the next few months, as vaccinations are sustained at a healthy pace. While financial markets are forward looking and have discounted these trends, consumers will likely adjust expectations with a lag and will want to see the reality of their own vaccination and lower COVID cases trends.  The surge in U.S. and UK economic activity will likely be echoed in real sector data for Q2 and Q3 in EZ countries, though with different magnitudes as the U.S. sugar rush high is also fueled by the $1.9trn Biden administration COVID relief package. While most DM countries have been exposed to the Kent variant, the Indian variant has been restricted to modest outbreaks apart from the UK where is has become the dominant variant.  New UK confirmed cases have ticked higher and need to be watched in the next few weeks, as any persistent surge could impact UK economic confidence.  However, data so far suggest that full vaccinated people in the UK are a very small proportion of those that have been hospitalized and hospital beds with COVID patients currently remains very low. 

Japan and Australia are lagging behind in the vaccination race and this creates a vulnerability.  Australia border policy and zero tolerance approach helps provides some breathing space, but the Kent and Indian variants are more transmissible than the original Wuhan variant that Australia successfully curbed in 2020.  Japan faces somewhat greater challenge, as current daily new COVID cases are elevated though off the mid may peak.  The next challenge is the July Olympics where 79k officials, support staff and press are scheduled to come from overseas, with a reluctance to postpone the Olympics until 2022.  This risks a 5th wave in Japan, given the low vaccination rate and low existing protection from previous infected cases.  

From a macro strategy standpoint, this divergence of trend on the margin has tended to be one factor in relative equity performance, with the Japanese equity market lagging this quarter as concerns grow about a delayed recovery. Even so, the situation would need to diverge more noticeably to protect further market divergence, as Japanese equity market current relative weakness reflects a correction after a great 2020 and the BOJ stopping the monthly purchases of ETFs.     

4Cast Ltd. and all of its affiliates (Continuum Economics) do not conduct “investment research” as defined in the FCA Conduct of Business Sourcebook (COBS) section 12 nor do they provide “advice about securities” as defined in the Regulation of Investment Advisors by the U.S. SEC. Continuum Economics is not regulated by the SEC or by the FCA or by any other regulatory body. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Nonetheless, Continuum Economics has an internal policy that prohibits “front-running” and that is designed to minimize the risk of receiving or misusing confidential or potentially material non-public information. The views and conclusions expressed here may be changed without notice. Continuum Economics, its partners and employees make no representation about the completeness or accuracy of the data, calculations, information or opinions contained in this report. This report may not be copied, redistributed or reproduced in part or whole without Continuum Economics’s express permission. Information contained in this report or relied upon in its construction may previously have been disclosed under a consulting agreement with one or more clients. The prices of securities referred to in the report may rise or fall and past performance and forecasts should not be treated as a reliable indicator of future performance or results. This report is not directed to you if Continuum Economics is barred from doing so in your jurisdiction. Nor is it an offer or solicitation to buy or sell securities or to enter into any investment transaction or use any investment service.
Analyst Certification
I, Mike Gallagher, the lead analyst certify that the views expressed herein are mine and are clear, fair and not misleading at the time of publication. They have not been influenced by any relationship, either a personal relationship of mine or a relationship of the firm, to any entity described or referred to herein nor to any client of Continuum Economics nor has any inducement been received in relation to those views. I further certify that in the preparation and publication of this report I have at all times followed all relevant Continuum Economics compliance protocols including those reasonably seeking to prevent the receipt or misuse of material non-public information.